This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Makkar, R. R. Articles by Kaul, S. Search for Related Content PubMed PubMed Citation Articles by Makkar, R. R. Articles by Kaul, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID HEPARIN Medline Plus Health Information Blood Thinners

(Circulation. 1997;95:1015-1021.)
© 1997 American Heart Association, Inc.

Articles

Effects of GP IIb/IIIa Receptor Monoclonal Antibody (7E3), Heparin, and Aspirin in an Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis

Raj R. Makkar, MD; Frank Litvack, MD; Neal L. Eigler, MD; Masato Nakamura, MD; Pamela A. Ivey, MD; James S. Forrester, MD; Prediman K. Shah, MD; Robert E. Jordan, PhD; Sanjay Kaul, MD

the Cardiovascular Interventional Research Center, the Division of Cardiology, Department of Medicine, The Burns and Allen Research Institute, Cedars-Sinai Medical Center, and UCLA School of Medicine, Los Angeles, Calif, and Centocor Inc, Malvern, Pa (R.E.J.).

Correspondence to Sanjay Kaul, MD, Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048. E-mail kaul@csmc.edu.

Background Thrombosis is an important limitation of metallic coronary stents, especially in smaller vessels in which shear rates are high. Monoclonal antibody to platelet glycoprotein IIb/IIIa receptor (7E3) has been shown to inhibit shear-induced platelet aggregation. In this study, we compared the effects of 7E3, heparin, and aspirin on stent thrombosis in an ex vivo arteriovenous shunt model of high-shear blood flow.

Methods and Results An ex vivo arteriovenous shunt was created in 10 anesthetized dogs. Control rough-surface slotted-tube nitinol stents (n=72) expanded to 2 mm in diameter in a tubular perfusion chamber were interposed in the shunt and exposed to flowing arterial blood at a shear rate of 2100 s^-1 for 20 minutes. The animals were treated with intravenous murine 7E3 (Fab')₂ (0.2, 0.4, and 0.8 mg/kg), heparin (100 U/kg), or aspirin (10 mg/kg). Effects of the test agents on thrombus weight, platelet aggregation, platelet P-selectin expression, bleeding time, and activated clotting time (ACT) were quantified. 7E3 reduced stent thrombosis by 95% (20±1 to 1±1 mg, P<.001) and platelet aggregation by 94% (14±2 to 1±1 , P<.001) at the highest dose (0.8 mg/kg). 7E3 significantly prolonged bleeding time but had no effect on ACT and platelet P-selectin expression. Heparin prolonged ACT but had no significant effect on stent thrombosis or platelet aggregation. Aspirin, although it inhibited platelet aggregation by 65%, had no effect on stent thrombosis (19±2 versus 20±1 mg in controls).

Conclusions 7E3 produced a dose-dependent inhibition of acute stent thrombosis under high-shear flow conditions. Stent thrombosis was resistant to heparin and aspirin. Thus, 7E3 may be an effective agent for preventing stent thrombosis.

Key Words: platelets • angioplasty • thrombosis

This article has been cited by other articles:

				T.-T. Hong, E. M. Driscoll, A. J. White, A. Sherigill, T. A. Giboulot, and B. R. Lucchesi Glycoprotein IIb/IIIa Receptor Antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-{[2-({4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl}amino)acetyl]amino}propanoic Acid Dihydrochloride (CRL42796), in Combination with Aspirin and/or Enoxaparin, Prevents Coronary Artery Rethrombosis after Successful Thrombolytic Treatment by Recombinant Tissue Plasminogen Activator J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 616 - 623. [Abstract] [Full Text] [PDF]

				T. Palmerini, M. A. Nedelman, L. E. Scudder, M. T. Nakada, R. E. Jordan, S. Smyth, R. E. Gordon, J. T. Fallon, and B. S. Coller Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates J. Am. Coll. Cardiol., July 17, 2002; 40(2): 360 - 366. [Abstract] [Full Text] [PDF]

				S. Chaturvedi, S. Sohrab, and A. Tselis Carotid Stent Thrombosis: Report of 2 Fatal Cases Stroke, November 1, 2001; 32(11): 2700 - 2702. [Abstract] [Full Text] [PDF]

				V. Rukshin, B. Azarbal, P. K. Shah, V. T. Tsang, M. Shechter, A. Finkelstein, B. Cercek, and S. Kaul Intravenous Magnesium in Experimental Stent Thrombosis in Swine Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1544 - 1549. [Abstract] [Full Text] [PDF]

				F. C. Tong, H. J. Cloft, G. J. Joseph, O. B. Samuels, and J. E. Dion Abciximab Rescue in Acute Carotid Stent Thrombosis AJNR Am. J. Neuroradiol., October 1, 2000; 21(9): 1750 - 1752. [Abstract] [Full Text]

				R. R. Azar, R. G. McKay, P. D. Thompson, J. A. Hirst, J. F. Mitchell, D. B. Fram, D. D. Waters, and F. J. Kiernan Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1996 - 2002. [Abstract] [Full Text] [PDF]

				V. Rukshin, P. K. Shah, B. Cercek, A. Finkelstein, V. Tsang, and S. Kaul Comparative Antithrombotic Effects of Magnesium Sulfate and the Platelet Glycoprotein IIb/IIIa Inhibitors Tirofiban and Eptifibatide in a Canine Model of Stent Thrombosis Circulation, April 23, 2002; 105(16): 1970 - 1975. [Abstract] [Full Text] [PDF]